Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

November 8, 2023

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 32 min

Earnings Call Speaker Segments

Operator

operator
#1

Morning, everyone. Valerie here, and I’ll be running today’s conference for you. Welcome to Cronos’ 2023 third quarter earnings conference call. This session is being recorded. Right now, I’ll hand things over to Shayne Laidlaw from Investor Relations. Go ahead, please.

Shayne Laidlaw

executive
#2

Thanks, Valerie, and I appreciate everyone being here today as we go over Cronos' financial and business results for the third quarter of 2023. With me on the call are Mike Gorenstein, our Chairman, President, and CEO, along with James Holm, our CFO. This morning Cronos put out a news release sharing our financial results, and that release has been filed on our EDGAR and SEDAR profile. You'll also find this information, together with the prepared remarks, posted on our website in the investor relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management's present expectations and assumptions, which carry risks and uncertainties that might lead actual results to differ materially from what those forward-looking statements project. The factors that might cause actual results to differ materially from expectations are set out in detail in our earnings materials and in our SEC filings, which you can access on our website, and those filings qualify in their entirety any forward-looking statements made on this call. Details on non-GAAP financial measures, including reconciliations to US GAAP, are likewise available in the earnings materials posted on our website.

Shayne Laidlaw

executive
#3

Finally, throughout this conference call we will be making statements that involve market share information. And unless otherwise stated, Hyfire provides all of the market share data. We'll now deliver prepared remarks, and after that we will transition into a question-and-answer session. With that, I'll hand things over to Mike Gorenstein, Chairman, President, and CEO of Cronos.

Mike Gorenstein

executive
#4

Thank you, Shayne, and good morning to everyone. I'd like to open by speaking about the horrifying and despicable terrorist attacks that took place in Israel in early October. All victims, the people who love them, and every Israeli remain in our thoughts as they strive to live free from terror both now and going forward. Cronos keeps putting the safety of our Israeli team and their families first, and we will do everything possible to stand behind them and our patients through this period. Even as our hearts go out to our Israeli team, we have stayed focused on expanding in existing markets where it makes sense and on launching new international markets like Germany and Australia. James will share more detail on the financial results when he speaks, but I want to touch on the wins this quarter. Revenue rose 22% year-over-year and 30% sequentially, reaching $24.8 million, powered by 40% year-over-year growth in Canada on the back of strength in pre-rolls, flower, and edibles. If we adjust gross margin for an inventory write-down tied to transitioning out of our Winnipeg facility, gross margin for the quarter would have come in at approximately 19%, a solid 260 basis point sequential improvement. Our balance sheet remains industry-leading, with roughly $840 million in cash and short-term investments.

Mike Gorenstein

executive
#5

Improved gross margin, reduced operating expenses, strong interest income, and better working capital management all underpin the strength of our balance sheet. We plan to build on that momentum through the rest of the year and into 2024 as we capture P&L efficiencies and additional interest income from our cash and short-term investments. In September, we shipped our first order of cannabis to Cansativa, our German distribution partner, and we're very excited to bring the Peace Naturals brand back to the German market. Cansativa ranks among the leading distributors of medical cannabis in Germany and has a network of approximately 2,000 high-volume cannabis-focused pharmacies that currently supply around 300,000 patients. Re-entering the German market, which has about 83 million people, is a significant milestone for us. We're working closely with the Cansativa sales team, who are excited about selling this brand in the market. Traction in the early innings of our launch is strong, and Cansativa has already received significant orders of Peace Naturals. Our goal is to keep expanding our reach and brand awareness in Germany with Cansativa's help so we establish our Peace Naturals brand as a top medical brand, similar to the brand's reputation in other international markets.

Mike Gorenstein

executive
#6

Bringing Cronos and our Peace Naturals brand back into the German market is going to put us in position to take advantage of this expanding opportunity, with extra upside potential stemming from future legislative changes — including if the German government reschedules cannabis and stops classifying it as a narcotic. Moving to Australia, we're currently filing our first order to Vitura, and the initial shipment to Australia is scheduled to go out later this month. As a reminder, Cronos holds roughly 10% of Vitura's common shares. Beyond establishing a commercial relationship with Vitura, we also got a cash dividend of approximately $346,000 in Q3, which makes this the second dividend we've received from Vitura. Vitura is the market-leading prescriber, patient, pharmacy, and supplier online platform, focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the cannabis ecosystem in the Australian medical cannabis market. According to the Australian government's Department of Health, the Australian market has seen medical cannabis patient approval through the authorized prescriber pathway rise by over 120% year-over-year to approximately 300,000 approvals as of the first half of 2023. Growing in this market is a top priority for Cronos, and we look forward to supplying our partners at Vitura with high quality cannabis products.

Mike Gorenstein

executive
#7

Now looking at Canada: in Q3 we kept carrying out our strategy of building a strong lineup of borderless products, with fresh launches and solid market results standing out. By October, Spinach held the top spot among brands in edibles and flower, ranked third in vapes, and stood as the third-ranked cannabis brand across Canada overall. Spinach edibles made up 17.9% of retail sales in the market during Q3, so we stayed the leader in that category. Our product is phenomenal and keeps rolling out new flavor profiles and cannabinoid blends — a textbook case of a borderless product that scales. During Q3, the newest SOURZ by Spinach flavor, pink lemonade, climbed to become the ninth most popular edible in Canada. All told, five of our edible products sit in the top 15. In dried flower, performance remains strong. Spinach ranked second among dried flower brands in Q3 at 5.8% market share, and three of our products are among the top 15 best-selling SKUs, headed by our GMO Cookies genetic in its various pack sizes. That Q3 momentum carried into October, and we were thrilled to report that Spinach climbed to become the number one flower brand in Canada.

Mike Gorenstein

executive
#8

Getting here took years of genetic breeding plus cultivation of the highest caliber — the very things that set our products apart from what else is on the market. Within vape, our Q3 share came in at 4.7%, moving us up to sixth place. On a monthly basis, Spinach climbed to fifth among vape brands in September, and what's even more striking, it advanced to third in October. We've put substantial effort into the vape portfolio across the past year, and seeing these robust market results at last feels great. Our 1-gram Blueberry Dynamite along with the new 1.2-gram format — both selling rapidly — have contributed to our share gains in vape. We intend to carry that momentum through the rest of 2023 and on into 2024, continuing to emphasize flavor-forward profiles and rare cannabinoids across our vapes. During this year we introduced multiple new items to strengthen the Spinach pre-roll lineup, among them Sonic Lemon Fuel three-pack pre-rolls and three additional infused pre-roll products: Pink Lemonade, Peach Punch and Strawberry Slurricane. In Q3, Spinach moved up to seventh place by market share among pre-roll brands — a meaningful gain versus where we stood in 2022 — driven by our flower, ranked number one, serving as the base for our pre-roll.

Mike Gorenstein

executive
#9

There’s room for us to expand within this category, and consumers and the industry are already paying more attention to our pre-rolls. Our Spinach brand took home Best Pre-Roll at the Grow Up Awards in October, for the Spinach Fully Charged Atomic GMO infused pre-rolls. The Grow Up Awards honor excellence across the cannabis industry, spotlighting outstanding achievements and innovation in a range of cannabis-related categories. Being acknowledged by the Grow Up Awards in this category makes us extremely proud. Taking the win with our pre-rolls matters a great deal to us, since we reworked our portfolio earlier this year so that what we offer improves and lifts the consumer experience. We keep putting our resources and expertise toward growing our innovation pipeline, and we look forward to launching new high-quality pre-rolls in the year ahead. In October, we brought out our much-anticipated THCV focused products in the vape and gummy categories. The Spinach FEELZ Full Tilt THC and THCV vapes and gumming are built to deliver a boosted and elevated high. Later in Q4, we intend to launch a THCV infused pre-roll, which adds one more offering to our robust pre-roll portfolio. The possibilities of THCV have us incredibly excited. These proprietary formulations represent a lot of work and provide a unique and differentiated experience, and we know consumers have been eager to try them.

Mike Gorenstein

executive
#10

With its Spinach FEELZ line of products infused with rare cannabinoids, Cronos has strengthened what it offers in gummies, vapes and pre-rolls beneath the Spinach brand umbrella. In Canada, Spinach FEELZ stands as a leading brand, and its portfolio includes rare cannabinoids — CBN, CBG, CBC and, as of now, THCV — with a good number of them produced through our proprietary fermentation methods. Earlier this year, we stated that we intended to launch our award-winning cannabis brand, Lord Jones, in the Canadian adult-use market. Our first product beneath this brand arrived in November, and we are delighted to return the Lord Jones brand to its roots through bold, elevated products focused on THC. The possibilities of cannabis are what inspire the Lord Jones brand. And we intend to use this brand in order to explore creative and unexpected avenues for bringing cannabis to the world and for shaping what the category becomes. Lord Jones products have been artfully crafted with scientific precision so that they deliver the purest products and the boldest flavors, providing a cannabis experience without parallel. We cannot wait for adult consumers to go above and beyond alongside us and to try these new products. Hash Fusions pre-rolls are the first product under the Lord Jones brand in Canada. Among adult consumers, hash products and premium pre-rolls are growing in popularity.

Mike Gorenstein

executive
#11

At present, hash ranks as the top solventless infusion, and within the pre-roll category it holds the number two spot among all infusions. With these Hash Fusion pre-rolls, the elevated true-to-plant consumption experience goes further than simply being delivered. An optimized ratio of premium high potency flower paired with complementary solventless ice water hash is what these pre-rolls are crafted with, preserving the bud's natural terpenes, and they come fitted with a reusable ceramic tip that helps cool the smoke. Extensive research and sensory testing went into this new product to deliver a smoother experience with bold flavors. Later this month, a Lord Jones live resin vape will also launch, featuring sought-after cultivars and delivering a flavorful full-spectrum live resin high. Our next highly anticipated edible, researched and developed across multiple years, is The Lord Jones Chocolate Fusions, launching early in 2024. In sensory panel testing, these products earned even more awards in their category than our award-winning and number one ranked Spinach SOURZ gummies. Mouthwatering, multi-textured artisanal chocolate and high-quality ingredients in three flavors — cookies and cream, dazzle-berry pop, and salted caramel crunch — will be featured in these edibles. Turning now to Cronos GrowCo, whose performance and cultivation remain strong. GrowCo reported preliminary unaudited revenue of roughly $6.2 million from non-Cronos customers during the third quarter.

Mike Gorenstein

executive
#12

Also, the credit facility Cronos gave GrowCo still has $69.4 million outstanding, after GrowCo repaid $1.1 million of principal in Q3. On top of that, GrowCo made a $1.2 million interest payment during Q3. GrowCo's strong financial performance—which generates equity pickup, interest payments and loan payback for Cronos—is a key part of our overall financial picture. In Israel, our team delivered impressive sequential growth in the third quarter even though patient growth was fairly flat and competitive pricing pressure persisted. Even with the war and the difficult situation, our team kept executing in market, holding distribution together and launching new products. Even so, the near-term priority that matters more is making sure we do what we can for Israeli employees, their families and the wider Israeli population. Now to the US market. We were glad to see the report of HHS' recommendation to the DEA proposing that cannabis be reclassified as a Schedule III drug under the Controlled Substances Act. Such reclassification would mark a major shift away from cannabis' present Schedule I status. Schedule III substances are acknowledged as having possible therapeutic benefits and are available by prescription. No matter the particulars of how federal regulation and commercialization of cannabis products develop, rescheduling would represent an enormous step for US cannabis.

Mike Gorenstein

executive
#13

With 3 quarters of the year now behind us, we're making solid progress toward the $20 million to $25 million in cost savings we previously guided for 2023, and we continue to expect an additional $10 million to $15 million in savings during 2024 as the benefits of the actions we took this year are fully realized. The wins this quarter delivered meaningful top line growth along with operating expense savings, which together drove a substantial improvement in cash flow from operations and put us in a stronger position to build a portfolio of borderless products supported by strategic infrastructure and global partnerships. These efforts, combined with an industry-leading balance sheet, leave us well set up to execute in any market. With that, I'll hand things over to James, who will walk you through our financials.

James Holm

executive
#14

Thanks, Mike, and good morning to everyone. I'll now walk through our results for the third quarter of 2023 compared with the same period a year earlier. Consolidated net revenue for the third quarter came in at $24.8 million, which is a 22% rise over the prior year and 30% higher than the second quarter. On a constant currency basis, consolidated net revenue grew 27% to $26 million. The growth in revenue was mainly the result of stronger cannabis flower and extract sales in Canada along with the start of cannabis shipments to Germany, partly offset by weaker cannabis flower sales in Israel stemming from competitive activity, fairly stagnant patient growth and political unrest. Consolidated gross profit as reported for the third quarter was $4 million, equal to a 16% gross margin, an improvement of $0.8 million versus the prior year. After adjusting for the $0.7 million inventory write-down tied to wind-down activities at Cronos Fermentation, gross margin would have come in at roughly 19%. The gain was mainly attributable to higher cannabis flower and extract sales in Canada, reduced cannabis biomass costs and ongoing supply chain optimization. We've shown steady sequential improvement on the gross margin line this year, moving from 15% in Q1 to 16% in Q2 and reaching 19% in Q3 on an adjusted basis.

James Holm

executive
#15

So with that, you're seeing some encouraging indicators of progress and stabilization, and we plan to carry that momentum forward into 2024. For the third quarter, consolidated adjusted EBITDA came in at negative $15.2 million, which is a $3.3 million gain versus the prior year. That gain was mainly the result of lower general and administrative and research and development expenses, along with better gross profit. As we noted earlier, we raised our target this year to cut operating expenses by $20 million to $25 million in 2023, and we expect to capture an incremental $10 million to $15 million in full year savings in 2024 after the significant cost savings initiatives we put in place in Q3. Now on to the balance sheet. The company closed the quarter with roughly $140 million in cash and short-term investments, down by about $1 million from the second quarter. Beyond maximizing the return on our cash, we received an interest payment on our GrowCo senior secured loan of $1.2 million and a principal repayment of $1.1 million, for total cash paid by GrowCo to Cronos of $2.3 million in Q3. Having the best balance sheet in the cannabis industry lets us make calculated strategic bets while we stay steadfastly focused on reducing cash burn.

James Holm

executive
#16

Turning now to the cash flow statement. Operating cash flow came in at roughly negative $180,000, which is a substantial improvement. We'll keep working to get better as we build an operation that's fully self-sustaining. Free cash flow — operating cash flow minus CapEx — was negative only $510,000, another great achievement. There are plenty of wins we can point to: market share gains, strong top line growth, steady gross margin improvement, OpEx reduction, cash balance optimization and improving cash flow from operations. Looking back on those improvements, I share Mike's confidence in the trajectory of the business and our preparedness for entry into new markets as they become available. With that, I'll turn it back to Mike.

Mike Gorenstein

executive
#17

Thank you, James. Globally, our brands are coming out on top, and that comes from the hard work of our employees in delivering best-in-class borderless products to the market. In Canada, the Spinach brand ranks within the top 10 for market share across every category where it competes — flower, pre-rolls, vapes and edibles. As regulations evolve, we're confident we'll be one of the best-positioned cannabis companies when it comes to capturing added market share in any market. Before we move to questions, I'd like to establish a baseline on what sits under the Cronos umbrella and where we are today. We ended the quarter with roughly $840 million in cash and short-term investments and no debt. Interest income came in above $13 million during Q3, and we expect to produce about $15 million in interest income during Q4. In Canada, for October 2023, our Spinach brand holds the following market share range. Taken as a whole, Spinach ranks as the number three cannabis brand, and that includes number one in edibles, number one in flower, number three in vapes and number seven in pre-rolls. We've introduced the Lord Jones brand into the Canadian adult use cannabis market, with products we know can win. In Israel, we have the leading medical brand, Peace Naturals, which posted $5.7 million in net revenue in Q3.

Mike Gorenstein

executive
#18

During this quarter, we sent cannabis shipments into Germany, and we expect to begin shipping to Australia during November, which broadens our international footprint. Our holding in PharmaCann stands at 6.3%, and that company ranks among the biggest private multi-state operators in the US; it currently sits on our balance sheet at $49 million. Half of the equity in Cronos GrowCo belongs to us, and that business is profitable; GrowCo made principal and interest payments to us of $2.3 million during Q3 against a loan balance still outstanding of $69.4 million. We hold roughly a 10% interest in Vitura, a top medical cannabis firm in Australia, carried on our books at $13 million. Lastly, Altria is our exclusive partner worldwide. When the market closed yesterday, Cronos showed a market capitalization of about $730 million along with an enterprise value of roughly negative $110 million. Our cash position has been stabilized and our cash flow trajectory sharply improved, which puts us among the cannabis companies best placed to capitalize on fresh market growth opportunities. With that said, I'll hand it over for questions.

Operator

operator
#19

Thanks. <<operator_script>> We’ll begin with a question from John Zamparo at CIBC. Your line is open.

John Zamparo

analyst
#20

Thank you, and good morning. I'd like to begin with Lord Jones. Seeing that brand launch in Canada is exciting. My assumption is that it will be positioned as a premium product. So I'm curious: in the research you're conducting, are you seeing consumers become more open or willing to shop within premium, rather than concentrating solely on THC per dollar?

Mike Gorenstein

executive
#21

Thanks, John. Yeah, good question. I think if we take a broad view of the Canadian market, clearly value holds the biggest share, obviously. But in our view that's a category facing growing pressure, while with premium I think there's a chance to really establish a distinct niche. I think it's a segment where we can succeed, and I think durable margins are more predictable there. And when we step back and think about building a borderless product portfolio, being able to succeed in that segment in Canada, where we do believe there's room, that will carry over into other markets much more easily than something like a value brand would. So we're very excited about what we can do with the edibles, and they're very differentiated, excited about what we can do with pre-rolls and vapes. And I think you're offering a proposition that's much different than just simply what's the potency per dollar.

John Zamparo

analyst
#22

All right, that's useful. Thank you. Now for my second question, which is broader and concerns the market: as you survey the Canadian landscape, are there any indications of more rational conduct in this sector? And does it seem to you that participants are either more likely to leave the market, or that operators are more likely to act more rationally where pricing is concerned?

Mike Gorenstein

executive
#23

Yeah. I don’t believe much has shifted on that front. What I would say is that a lot of exits are occurring right now. I’m not sure that’s really due to companies’ decision-making — perhaps it’s investors who simply aren’t funding losses anymore, along with bankruptcy processes running their course. But I do think that whatever the cause, exits are happening, and in my view that will bring about some rationalization. So it’s really about ensuring we make it through to the other side, and for us, keeping our focus on the consumer is how we get there. And I think the macro environment will unfold as it does.

John Zamparo

analyst
#24

Got it. Okay. Thank you so much. I'll share that with them.

Operator

operator
#25

Thanks. Just a moment. We now have a question from Vivien Azer at TD Cowen. Your line is open.

Vivien Azer

analyst
#26

Thank you. Good morning. So to begin with, I'd like to address one administrative point, if I may. Could you share your thoughts on the revenue benefit that might have been realized during the quarter from sell-in on borderless products? Thanks.

James Holm

executive
#27

Hey, Valerie — this is James. Sorry, Vivien. There’s very little benefit coming from Lord Jones. You’ll see that begin to pick up in Q4 and after that. So we truly expect that to be a big driver going into 2024.

Vivien Azer

analyst
#28

Got it. That makes the growth you saw in the Canadian market even more encouraging, since it came without that. So my follow-up, then: given the share gains you're seeing across several key categories, plus deflation in flower prices, could we go back over gross margin by product type? Specifically, if you could just size up how we should think about the gross margin differences, or simply rank them, among flower, pre-rolls, vapes and edibles. Thanks.

James Holm

executive
#29

Sure. So yes, our edibles — the number one edibles — remain the products with the highest margins, correct? And we're constantly working to make those even better. We do see — I'll just note that the Lord Jones Choco Bite is also contributing positively to the overall company margin. After that comes vapes, and once again we're focused on optimizing that portfolio. We just mentioned the 1.2-gram launches and are steadily gaining share in that category. Then pre-rolls come very close behind. And again, we're working to optimize that structure as we keep evaluating the supply chain and further optimize wherever there's opportunity. And then last but not least, flower. And again, margins there are still decent, but that's our lowest category at present, as you'd expect given the current price competition. But with all that said, right, our flower is outstanding, still keeps winning against the competition and is getting better in that category.

Vivien Azer

analyst
#30

That’s great. Thanks so much.

Operator

operator
#31

Thanks. Just a second, please. <<operator_script>> We now have a question from <<inaudible>> at Canaccord Genuity. Your line is open.

Analyst

analyst
#32

Hi there, thank you, and good morning. This is <<inaudible>> speaking for Matt Bottomley. I wanted to return to something Jim mentioned about the Canadian adult vape market. Last month marked 5 years since recreational legalization in the country, and we've noticed more media coverage of multiple licensed producers leaving the market because of persistent headwinds in the sector. So I'd like to ask for your view on that. Have you observed a lower degree of competition at the licensed producer level? And, I suppose, flowing through to pricing, has that affected your capacity to price any of your products higher? Thanks.

Mike Gorenstein

executive
#33

Sure, thank you. I believe we've observed quite a few players leaving the market. And when you consider bankruptcies across Canada overall, cannabis certainly ranks near the top in terms of how many there are. So yes, exits are happening, but at the same time a wave of new entrants has come in. They simply described it as backlog. So this hasn't been an immediate thing. And the reality, I think, is that in the short to medium term you will keep seeing supply exceed demand. But what I think happens is that this really shows up in the value tier. So there's a great deal of competition and a great deal of irrational behavior around the big pack formats for lower quality products, yet you're seeing opportunity — we still see opportunities in main stream and in premium to keep taking share and to keep growing. And while I'm not sure you're seeing, let's say, base opportunities to raise prices, I think we are bringing costs down. And as you innovate, that's where I think you're able to have some pricing power. So for us, the margin improvement and the market share growth are really driven by innovation, and innovation has truly been king for us.

Mike Gorenstein

executive
#34

So I think that's going to keep happening as we move forward. And in time, I believe you'll see that rationalization play out. A lot of these companies, I think, won't be able to remain in the market. I still expect there will be a diverse set of companies that are able to take part. And as things ultimately normalize, I think the overall market opportunity will improve dramatically — but we've kind of learned that it doesn't make sense for us to keep punting and waiting for that. We need to be able to do it now. And that's why focusing on getting cost down on growing and improving margins has been so important for us.

Yewon Kang

analyst
#35

Understood, thanks. Moving over to the international side now. We've noticed additional media coverage suggesting Canadian licensed producers have been sending more supply into Europe. So I suppose my question is whether that has had an impact on the prices you're able to command for the exports you supply to your European partners, Cansativa included, during this quarter? And could you also share any further thoughts on what you're observing in Australia regarding pricing for exports entering that market? Thank you.

Mike Gorenstein

executive
#36

Sure. So I think if you look at it next to Canada, definitely, once excise tax isn't included and provincial distributors aren't in the picture, what you're seeing is something that's margin accretive overall. And even though it's not the way it was a few years back, when just one or two companies could ship, I think it still really comes down to having a quality product. As more suppliers have appeared in these markets, consumers have also gotten, let's say, more sophisticated and aware of what they want. And I think that works in our favor. We appreciate that consumers are basing their choices on product quality, since in the end, we believe that will generate more momentum and more share for us. So I think with medical, you're almost always likely to see a better margin profile than in a more developed adult-use market. And we haven't really observed anything that turns that trend around. So whether it's Israel, Germany, or Australia, we still see plenty of positives overall from flower.

Operator

operator
#37

Thank you. At this point, I see no additional questions. Everyone, that brings today's call to an end. We appreciate all of you joining us. You're welcome to disconnect now. Have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.